Rapid protocol for irinotecan desensitization: a case report and literature review

Irinotecan—an antineoplastic drug that inhibits topoisomerase I—is widely used to treat gastrointestinal malignancies. IgE-mediated hypersensitivity reactions (HSRs) to irinotecan are rarely described to date and successfully treated by a rapid drug desensitization (RDD) protocol. Chemotherapy desensitization is reported as a safe and effective way to reintroduce a culprit drug that often represents the firstline drug therapy. RDD should always be considered, particularly when there are no other valid therapeutic approaches in terms of life expectancy and quality of life. The RDD induces a temporary tolerance to drug allergens by gradually reintroducing a small amount

• Publication year

  2020

• Venue

  Allergo Journal International

• Publication date

  2020-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s40629-020-00156-0
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Breakthrough reactions during rapid drug desensitization: Clinical outcome and risk factors.

  2019cited by this paper
• Rapid Drug Desensitization with Chemotherapeutics (Platins, Taxanes, and Others): A Single-Center Retrospective Study

  2019cited by this paper
• Successful Desensitization to Irinotecan After Severe Hypersensitivity Reaction.

  2016cited by this paper
• Successful Desensitization Protocol for Hypersensitivity Reaction Caused by Irinotecan in a Patient With Metastatic Colorectal Cancer.

  2015cited by this paper
• Delving into cornerstones of hypersensitivity to antineoplastic and biological agents: value of diagnostic tools prior to desensitization

  2015cited by this paper
• Rapid drug desensitization for hypersensitivity reactions to chemotherapy and monoclonal antibodies in the 21st century.

  2014cited by this paper
• Rapid drug desensitization for hypersensitivity reactions to chemotherapy and monoclonal antibodies in the 21st century.

  2014cited by this paper
• Acetylsalicylic acid and montelukast block mast cell mediator-related symptoms during rapid desensitization.

  2009cited by this paper
• Hypersensitivity reactions to antineoplastic agents: an overview

  2009cited by this paper
• Clinical features and severity grading of anaphylaxis.

  2004cited by this paper
• Food , drug , insect sting allergy , and anaphylaxis Hypersensitivity reactions to chemotherapy : Outcomes and safety of rapid desensitization in 413 cases

  year unknowncited by this paper

• Successful Desensitization to Irinotecan in a Patient with Metastatic Esophageal Squamous Cell Carcinoma and a History of Anaphylaxis in Response to Irinotecan—Case Report and Literature Review

  2024cites this paper
• Irinotecan

  2021cites this paper
• COVID-19-Impfungen: Replizierend oder Nichtreplizierend?

  2021cites this paper